An EGM held on April 15 resolved a share issue directed to existing shareholders. Fully subscribed the issue will bring SEK 29.5 million gross to the company.

David Bejker CEO, said: “Affibody has during the first quarter been able to move a number of business development discussions forward while in parallel reduced the financial uncertainty for the company by renegotiating existing agreements. We appreciate the strong support from investors in the ongoing share issue which also highlights the potential of our platforms”.

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor Growth Capital.